{"organizations": [], "uuid": "11311673d274aa3cda1b060e3d74472152cf5303", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mologen-signs-license-deal-for-chi/brief-mologen-signs-license-deal-for-china-with-oncologie-for-lead-compound-lefitolimod-idUSASM000J95", "country": "US", "domain_rank": 408, "title": "Mologen Signs License Deal For China With Oncologie For Lead Compound Lefitolimod", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.287, "site_type": "news", "published": "2018-02-13T23:18:00.000+02:00", "replies_count": 0, "uuid": "11311673d274aa3cda1b060e3d74472152cf5303"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mologen-signs-license-deal-for-chi/brief-mologen-signs-license-deal-for-china-with-oncologie-for-lead-compound-lefitolimod-idUSASM000J95", "ord_in_thread": 0, "title": "Mologen Signs License Deal For China With Oncologie For Lead Compound Lefitolimod", "locations": [], "entities": {"persons": [], "locations": [{"name": "china", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "mologen ag", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - MOLOGEN AG:\n* SIGNS LICENSE DEAL FOR CHINA AND GLOBAL CO-DEVELOPMENT AGREEMENT WITH ONCOLOGIE FOR LEAD COMPOUND LEFITOLIMOD\n* SIGNED AGREEMENT IS CONDITIONAL UPON AN INITIAL PAYMENT OF EUR 3 MILLION RECEIVED BY MOLOGEN\n* TOTAL PAYMENTS CAN AMOUNT TO ABOVE EUR 100 MILLION AND WILL BE PAID OVER SEVERAL YEARS\n* ADDITIONALLY, MOLOGEN WILL RECEIVE LOW DOUBLE DIGIT ROYALTIES ON SALES Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T23:18:00.000+02:00", "crawled": "2018-02-14T12:18:04.020+02:00", "highlightTitle": ""}